Brief: Xilio Starts Phase 2 Trial for XTX301, Hits $17.5M Milestone in Gilead License Deal
09/09/2025 12:37
Sept 9 (Reuters) - Xilio Therapeutics Inc XLO.O: XILIO THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 TRIAL FOR EFARINDODEKIN ALFA (XTX301), A TUMOR-ACTIVATED IL-12, AND ACHIEVEMENT OF $17.5 MILLION DEVELOPMENT MILESTONE UNDER EXCLUSIVE LICENSE AGREEMENT WITH GILEAD Source text: ID:nGNX1ffbCC Further company coverage: XLO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla